


Cell Marque™ Tissue Diagnostics


SMAD4 (MRQ-72)

Rabbit Monoclonal Antibody


Mothers Against Decapentaplegic Homolog 4 (SMAD4) is a transcription factor that is involved in TGFβ signaling pathways and acts as a tumor suppressor¹. SMAD4 is commonly expressed in a variety of cancers, including pancreatic ductal adenocarcinoma (PDA), colorectal carcinoma (CRC), hepatocellular carcinoma (HCC), and gastric carcinomas, as well as non-neoplastic liver, pancreas, and colon.²⁻⁵ However, a loss of expression has been observed in a subset of PDA, CRC and gastric carcinomas due to a variety of mutations including nonsense, missense, deletions, and splice site changes.^{2-4,6} In contrast, SMAD4 is over-expressed in HCC compared to the weak expression that is exhibited in non-neoplastic liver.⁵



Pancreatic Ductal Adenocarcinoma
(loss of expression)



Pancreatic Tissue



Pancreatic Tissue

Ordering Information:

Description	Cat No.
0.1 mL concentrate	487R-94
0.5 mL concentrate	487R-95
1.0 mL concentrate	487R-96
1.0 mL predilute ready-to-use	487R-97
7.0 mL predilute ready-to-use	487R-98



Intended Use:

SMAD4 (MRQ-72) Rabbit Monoclonal Antibody is intended for laboratory use in the detection of the SMAD4 protein in formalin-fixed, paraffin-embedded human tissue stained in qualitative immunohistochemistry (IHC) testing. The results using this product should be interpreted by a qualified pathologist in conjunction with the patient's relevant clinical history, other diagnostic tests and proper controls.

Product Information:

Visualization: Cytoplasmic, Nuclear

Controls: Pancreas

Dilution Range: 1:25-1:50

Associated Specialty: Gastrointestinal (GI) Pathology

References:

1. Liu F, et al. Dual role of the Smad4/DPC4 tumor suppressor in TGF β -inducible transcriptional complexes. *Genes Dev* 1997;11(23):3157-3167
2. Ritterhouse LL, et al. Loss of SMAD4 protein expression in gastrointestinal and extragastrointestinal carcinomas. *Histopath* 2019;75(4):546-551
3. Salovaara R, et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. *Gut* 2002;51(1):56-59
4. Kim YH, et al. Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. *Ann Oncol* 2004;15(4):574-580
5. Torbenson M, et al. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling. *Hum Pathol.* 2002;33(9):871-876
6. Woodford-Richens KL, et al. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. *Proc Natl Acad Sci USA* 2001;98(17):9719-23

Please note: The product featured belongs to the group in vitro diagnostic (IVD) medical devices. The product is FDA Class 1 in the US.

USA

Toll Free: 800.665.7284

Phone: 916.746.8900

Fax: 916.746.8989

Email: service@cellmarque.com

www.cellmarque.com

MilliporeSigma

400 Summit Drive

Burlington, MA 01803

SigmaAldrich.com

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the vibrant M, Sigma-Aldrich, and Cell Marque are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

